基层医疗中男性尿路感染管理指南:缺乏国际共识的系统综述
该系统综述纳入29部更新的区域/国家指南,评估其方法学质量与推荐强度。结果显示男性尿路感染定义与治疗缺乏国际共识,指南多基于专家意见,氟喹诺酮疗程从28天逐渐缩短至10-14天,但退热与否及短疗程策略仍存分歧。
要点
- 男性尿路感染管理缺乏国际共识,指南多基于专家意见而非高质量证据。
- 发热性男性尿路感染接受氟喹诺酮10-14天,尽管存在抗菌药物耐药高风险。
- 斯堪的纳维亚指南推荐3-5天短疗程非氟喹诺酮方案,但缺乏干预试验验证。
核心结论
- 男性尿路感染的定义与治疗不精确,缺乏国际共识,指南主要基于专家意见。
- 发热性男性尿路感染接受14天氟喹诺酮治疗,尽管抗菌药物耐药风险高。
- 非氟喹诺酮治疗和/或非发热性男性尿路感染短疗程尚未被广泛接受。
研究设计与样本
- 2021年对Medline(PubMed)、EMBASE及灰色文献指南数据库进行国际系统文献综述。
- 由2名独立评审使用AGREE II工具评估每部指南的方法学质量。
- 从1678条记录中筛选1558条,评估134条,最终纳入29部更新的指南(Medline 13部,EMBASE 0部,灰色文献16部)。
主要发现
- 14部(48%)指南方法学质量高,18部(62%)使用分级系统方法。
- 男性尿路感染分类包括解剖分类(膀胱炎、前列腺炎、肾盂肾炎)和症状分类(基于症状强度与耐受性)。
- 过去20年,发热性男性尿路感染氟喹诺酮疗程从28天逐渐缩短至10-14天,成为国际金标准。
- 斯堪的纳维亚国家指南推荐3-5天短疗程非氟喹诺酮治疗:匹美西林、呋喃妥因或甲氧苄啶。
- 法语国家指南采用观察等待策略,并建议无论是否发热均使用氟喹诺酮治疗男性尿路感染。
关键数值与推荐
- 所有男性尿路感染管理均系统进行尿细菌学检查。
- 前列腺特异性抗原检测并非男性尿路感染阳性诊断所必需。
- 发热性男性尿路感染:氟喹诺酮10-14天为国际金标准。
- 斯堪的纳维亚指南:非氟喹诺酮短疗程3-5天(匹美西林、呋喃妥因或甲氧苄啶)。
临床怎么用
- 基层医生应知晓男性尿路感染管理缺乏统一国际标准,需结合当地指南与耐药情况决策。
- 对发热性男性尿路感染,氟喹诺酮10-14天仍是广泛接受的方案,但需警惕耐药风险。
- 非发热性男性尿路感染/膀胱炎的定义存在争议,影响抗生素类型与疗程选择。
- 尿细菌学检查应系统进行,前列腺特异性抗原不用于男性尿路感染阳性诊断。
局限性
- 指南主要基于专家意见,科学证据缺乏导致共识与分歧并存。
- 男性尿路感染管理并非基层医疗特有,定义和治疗建议因各国处方实践而异。
- 需在基层医疗开展干预性试验以确认非发热性男性尿路感染短疗程非氟喹诺酮治疗的有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of adult male urinary tract infections (mUTIs) in primary care lacks international consensus. The main objective of this study was to describe the different guidelines for the diagnosis and management of mUTIs in primary care, to assess their methodological quality, and to describe their evidence-based strength of recommendation (SoR). METHODS: An international systematic literature review of the electronic databases Medline (PubMed) and EMBASE, and gray-literature guideline-focused databases was performed in 2021. The Appraisal of Guidelines for Research and Evaluation (AGREE II) assessment tool was used by 2 independent reviewers to appraise each guideline. RESULTS: From 1,678 records identified, 1,558 were screened, 134 assessed for eligibility, and 29 updated guidelines met the inclusion criteria (13 from Medline, 0 from EMBASE, and 16 from gray literature). Quality assessment revealed 14 (48%) guidelines with high-quality methodology. A grading system methodology was used in 18 (62%) guidelines. Different classifications of mUTIs are described, underlining a lack of international consensus: an anatomic classification (cystitis, prostatitis, pyelonephritis) and a symptomatic classification (approach based on the intensity and tolerance of symptoms). The duration of antibiotic treatment for febrile mUTIs has been gradually reduced over the last 20 years from 28 days to 10-14 days of fluoroquinolones (FQ), which has become the international gold standard. Guidelines from Scandinavian countries propose short courses (3-5 days) of FQ-sparing treatments: pivmecillinam, nitrofurantoin, or trimethoprim. Guidelines from French-speaking countries use a watchful waiting approach and suggest treating mUTIs with FQ, regardless of fever. CONCLUSIONS: This lack of scientific evidence leads to consensus and disagreement: 14 days of FQ for febrile mUTIs is accepted despite a high risk of antimicrobial resistance, but FQ-sparing treatment and/or short treatment for afebrile mUTIs is not. The definition of afebrile UTIs/cystitis is debated and influences the type and duration of antibiotic treatment recommended. The definition and the treatment of adult male urinary tract infections (mUTIs) are imprecise compared with female UTIs. We aimed to describe the different guidelines for the diagnosis and management of mUTIs in primary care and to assess their methodological quality. Our international systematic review included 29 updated regional/national guidelines. The management of male UTIs is not specific to primary care. Guidelines are mainly based on expert opinion, so definition and therapeutic proposals differ according to the prescribing practices of each country. Different classifications of mUTIs are described, underlining a lack of international consensus: an anatomic classification (cystitis, prostatitis, pyelonephritis) and a symptomatic classification (approach based on the intensity and tolerance of symptoms). Cytobacteriological examination of urine is systematically performed in the management of all mUTIs. A prostate-specific antigen test is not necessary for the positive diagnosis of mUTI. Over the past 20 years, the duration of treatment with fluoroquinolone antibiotics has decreased from 4 to 2 weeks. Fluoroquinolones (FQ) remain the reference treatment but there is a high risk of antimicriobial resistance. Guidelines from Scandinavian countries propose short courses (3–5 days) of FQ-sparing treatments: pivmecillinam, nitrofurantoin, or trimethoprim. Guidelines from French-speaking countries use a watchful waiting approach and suggest treating mUTIs with FQ, regardless of fever. This lack of scientific evidence leads to consensus and disagreement: 14 days of FQ for febrile mUTIs is accepted despite a high risk of antimicrobial resistance, but FQ-sparing treatment and/or short treatment for afebrile mUTIs is not. The promotion of interventional trials will be necessary in primary care to confirm the efficacy of short treatment without FQ in afebrile mUTIs.
引用
- Soudais B, Ribeaucoup F, Schuers M, et al. Guidelines for the management of male urinary tract infections in primary care: a lack of international consensus-a systematic review of the literature. Fam Pract. 2023. PMID: 35833228. doi:10.1093/fampra/cmac068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。